Cardiology Xagena

Xagena Mappa
Xagena Newsletter

Crestor can reduce plaques that cause myocardial infarction

Findings from the ASTEROID trial showed that patients with heart disease who took the maximum dose of Rosuvastatin ( 40 mg per day; Crestor ) for 24 months and achieved on average LDL cholesterol levels below 70 mg/dL and significant increases in HDL cholesterol, had a mean reduction in the plaques that caused blockages in their arteries.

The study used two different imaging techniques to measure different segments of the coronary arteries. Both showed reduction of plaque.

ASTEROID ( A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden ) was designed to determine the effects of treatment with Rosuvastatin on progression of coronary atherosclerosis in patients who had a clinically indicated cardiac catheterization that showed angiographic evidence of coronary artery disease ( CAD ).
This study examined whether Rosuvastatin could regress coronary atherosclerosis as assessed by intravascular ultrasound ( IVUS, the primary endpoint ) and quantitative coronary angiography ( QCA, a secondary endpoint ).
As previously reported, IVUS assessment of a single coronary artery with